Lower urinary tract symptoms in men

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Hollingsworth, John M ^a   Wilt, Timothy J ^b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Minneapolis VA Center for Chronic Disease Outcomes Research   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; PHENOXYBENZAMINE; PROSTATE SPECIFIC ANTIGEN; SILODOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; MUSCLE RELAXANT AGENT; PHOSPHODIESTERASE V INHIBITOR;

ADVERSE OUTCOME; AGE; CLINICAL ASSESSMENT; CLINICAL FEATURE; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG SAFETY; EJACULATION DISORDER; FIBROSIS; GYNECOMASTIA; HUMAN; LASER PROSTATECTOMY; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; MALE; MEN'S HEALTH; MINIMALLY INVASIVE SURGERY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYTOTHERAPY; POSTVOID RESIDUAL URINE VOLUME; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; RISK FACTOR; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL NEEDLE ABLATION; TRANSURETHRAL RESECTION; COMPLICATION; LOW LEVEL LASER THERAPY; LOWER URINARY TRACT SYMPTOMS; PROCEDURES; PROSTATIC HYPERPLASIA; PROSTATISM; SUBURETHRAL SLING;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-ANTAGONISTS; HUMANS; LASER THERAPY; LOWER URINARY TRACT SYMPTOMS; MALE; MUSCARINIC ANTAGONISTS; NEUROMUSCULAR AGENTS; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATIC HYPERPLASIA; PROSTATISM; SUBURETHRAL SLINGS; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 84907365733     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g4474     Document Type: Review

References (120)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-9. (Pubitemid 14026148)
2. Abrams P. LUTS, BPH, BPE, BPO: a plea for the logical use of correct terms. Rev Urol 1999;1:65.
3. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in america project: benign prostatic hyperplasia. J Urol 2008;179(5 suppl):S75-80. (Pubitemid 351483917)
4. Moyad MA, Lowe FC. Educating patients about lifestyle modifications for prostate health. Am J Med 2008;121(8 suppl 2):S34-42.
5. Parsons JK, Mougey J, Lambert L, Wilt TJ, Fink HA, Garzotto M, et al. Lower urinary tract symptoms increase the risk of falls in older men. BJU Int 2009;104:63-8.
6. Hollingsworth JM, Hollenbeck BK, Daignault S, Kim SP, Wei JT. Differences in initial benign prostatic hyperplasia management between primary care physicians and urologists. J Urol 2009;182:2410-4.
7. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989;2:33-50. (Pubitemid 20075619)
8. Haylen BT, Ashby D, Sutherst JR, Frazer MI, West CR. Maximum and average urine flow rates in normal male and female populations - the Liverpool nomograms. Br J Urol 1989;64:30-8. (Pubitemid 19177139)
9. Girman CJ, Panser LA, Chute CG, Oesterling JE, Barrett DM, Chen CC, et al. Natural history of prostatism: urinary flow rates in a community-based study. J Urol 1993;150:887-92. (Pubitemid 23241291)
10. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860-4. (Pubitemid 23234116)
11. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993;150:85-9. (Pubitemid 23175978)
12. Bosch JL, Hop WC, Kirkels WJ, Schroder FH. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology 1995;46(3 suppl A):34-40.
13. Warren K, Burden H, Abrams P. Lower urinary tract symptom: still too much focus on the prostate? Curr Opin Urol 2014;24:3-9.
14. Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 2009;104:352-60.
15. Chang RT, Kirby R, Challacombe BJ. Is there a link between BPH and prostate cancer? Practitioner 2012;256:13-6, 12.
16. Gillatt D, Reynard JM. What is the "normal range" for prostate-specific antigen? Use of a receiver operating characteristic curve to evaluate a serum marker. Br J Urol 1995;75:341-6.
17. Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol 1994;140:989-1002. (Pubitemid 24373003)
18. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002;168:599-604. (Pubitemid 34793304)
19. Seim A, Hoyo C, Ostbye T, Vatten L. The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study. BJU Int 2005;96:88-92. (Pubitemid 40942875)
20. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006;91:2562-8. (Pubitemid 44024618)
21. Cohen P, Peehl DM, Rosenfeld RG. The IGF axis in the prostate. Horm Metab Res 1994;26:81-4. (Pubitemid 24089214)
22. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001;54:935-44. (Pubitemid 32771319)
23. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39:151-8. (Pubitemid 32171181)
24. Wichi RB, De Angelis K, Jones L, Irigoyen MC. A brief review of chronic exercise intervention to prevent autonomic nervous system changes during the aging process. Clinics (Sao Paulo) 2009;64:253-8.
25. Barry MJ, Fowler FJ, Jr., O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The measurement committee of the American Urological Association. J Urol 1992;148:1549-57; discussion 1564.
26. Barry MJ, Williford WO, Chang Y, Machi M, Jones KM, Walker-Corkery E, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995;154:1770-4.
27. Maserejian NN, Wager CG, Giovannucci EL, Curto TM, McVary KT, McKinlay JB. Intake of caffeinated, carbonated, or citrus beverage types and development of lower urinary tract symptoms in men and women. Am J Epidemiol 2013;177:1399-410.
28. Soda T, Masui K, Okuno H, Terai A, Ogawa O, Yoshimura K. Efficacy of nondrug lifestyle measures for the treatment of nocturia. J Urol 2010;184:1000-4.
29. Brown CT, Yap T, Cromwell DA, Rixon L, Steed L, Mulligan K, et al. Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ 2007;334:25.
30. Wilt TJ, Howe W, MacDonald R. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU Int 2002;89:214-25. (Pubitemid 34158452)
31. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998;338:557-63. (Pubitemid 28114643)
32. Filson CP, Hollingsworth JM, Clemens JQ, Wei JT. The efficacy and safety of combined therapy with alpha-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. J Urol 2013;190:2153-60.
33. Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003.
34. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975;47:193-202.
35. Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, et al. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol 1994;45:703-8.
36. Lepor H, Shapiro E. Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia. J Urol 1984;132:1226-9. (Pubitemid 15213903)
37. Shapiro E, Lepor H. Alpha 2 adrenergic receptors in hyperplastic human prostate: identification and characterization using [3H] rauwolscine. J Urol 1986;135:1038-42. (Pubitemid 16077246)
38. American Urological Association Guideline. Management of benign prostatic hyperplasia (BPH). Revised. 2010. www.auanet.org/common/pdf/education/clinical- guidance/Benign-Prostatic-Hyperplasia.pdf.
39. European Association of Urology. Guidelines on the treatment of non-neurogenic male LUTS, 2011. http://www.uroweb.org/gls/pdf/12-Male-LUTS.pdf. .
40. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003;92:257-61. (Pubitemid 36966589)
41. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98. (Pubitemid 37542987)
42. Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 1978;50:551-4. (Pubitemid 9073879)
43. MacDonald R, Wilt TJ, Howe RW. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU Int 2004;94:1263-70. (Pubitemid 40052090)
44. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998;51:892-900. (Pubitemid 28240845)
45. Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol 1998;160:1701-6. (Pubitemid 128746741)
46. Wilt TJ, MacDonald R, Nelson D. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. J Urol 2002;167:177-83. (Pubitemid 34024526)
47. Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernandez E. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 2011;59:342-52.
48. Lepor H, Lepor NE, Hill LA, Trohman RG. The QT interval and selection of alpha-blockers for benign prostatic hyperplasia. Rev Urol 2008;10:85-91.
49. Van Moorselaar RJ, Hartung R, Emberton M, Harving N, Matzkin H, Elhilali M, et al. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005;95:603-8. (Pubitemid 40311481)
50. Sakata K, Morita T. Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia. BMC Urol 2012;12:29.
51. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005;31:664-73. (Pubitemid 40719407)
52. Cantrell MA, Bream-Rouwenhorst HR, Steffensmeier A, Hemerson P, Rogers M, Stamper B. Intraoperative floppy iris syndrome associated with alpha1-adrenergic receptor antagonists. Ann Pharmacother 2008;42:558-63. (Pubitemid 351521970)
53. Issa SA, Hadid OH, Baylis O, Dayan M. Alpha antagonists and intraoperative floppy iris syndrome: a spectrum. Clin Ophthalmol 2008;2:735-41.
54. Chang DF, Braga-Mele R, Mamalis N, Masket S, Miller KM, Nichamin LD, et al. Clinical experience with intraoperative floppy-iris syndrome. Results of the 2008 ASCRS member survey. J Cataract Refract Surg 2008;34:1201-9. (Pubitemid 351847824)
55. Coffey DS, Walsh PC. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 1990;17:461-75. (Pubitemid 20220190)
56. Shapiro E. Embryologic development of the prostate. Insights into the etiology and treatment of benign prostatic hyperplasia. Urol Clin North Am 1990;17:487-93. (Pubitemid 20220192)
57. Cabot AT. II. The question of castration for enlarged prostate. Ann Surg 1896;24:265-309.
58. Schroeder FH, Westerhof M, Bosch RJ, Kurth KH. Benign prostatic hyperplasia treated by castration or the LH-RH analogue buserelin: a report on 6 cases. Eur Urol 1986;12:318-21. (Pubitemid 16007881)
59. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996;335:533-9.
60. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41. (Pubitemid 35292169)
61. Fenter TC, Davis EA, Shah MB, Lin PJ. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged ≥65 years. Am J Manag Care 2008;14(5 suppl 2):S154-9.
62. Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 2011;108:388-94.
63. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.
64. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24. (Pubitemid 36859473)
65. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375-83. (Pubitemid 351767184)
66. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61:119-26. (Pubitemid 36151726)
67. Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 2006;175:217-20; discussion 220-1.
68. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57:123-31.
69. Fullhase C, Chapple C, Cornu JN, De Nunzio C, Gratzke C, Kaplan SA, et al. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol 2013;64:228-43.
70. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006;49:651-8. (Pubitemid 43374725)
71. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296:2319-28. (Pubitemid 44749359)
72. Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005;47:824-37. (Pubitemid 40745353)
73. Vallancien G, Emberton M, Harving N, van Moorselaar RJ. Sexual dysfunction in 1274 European men suffering from lower urinary tract symptoms. J Urol 2003;169:2257-61. (Pubitemid 36576765)
74. Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011;30:292-301.
75. Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, De Vita G, et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 2010;7(1 Pt 1):59-69.
76. Bales GT, Christiano AP, Kirsh EJ, Gerber GS. Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago. Urology 1999;54:86-9. (Pubitemid 29323338)
77. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008;12:1-23.
78. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998;280:1604-9. (Pubitemid 28520650)
79. Lapi F, Gallo E, Giocaliere E, Vietri M, Baronti R, Pieraccini P, et al. Acute liver damage due to Serenoa repens: a case report. Br J Clin Pharmacol 2010;69:558-60.
80. Jibrin I, Erinle A, Saidi A, Aliyu ZY. Saw palmetto-induced pancreatitis. South Med J 2006;99:611-2. (Pubitemid 43999924)
81. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006;354:557-66. (Pubitemid 43209103)
82. Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA 2011;306:1344-51.
83. MacDonald R, Tacklind JW, Rutks I, Wilt TJ. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int 2012;109:1756-61.
84. Strope SA, Elliott SP, Saigal CS, Smith A, Wilt TJ, Wei JT. Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population. Urology 2011;78:3-9.
85. Nitti VW. Pressure flow urodynamic studies: the gold standard for diagnosing bladder outlet obstruction. Rev Urol 2005;7(suppl 6):S14-21.
86. Porru D, Madeddu G, Campus G, Montisci I, Scarpa RM, Usai E. Evaluation of morbidity of multi-channel pressure-flow studies. Neurourol Urodyn 1999;18:647-52. (Pubitemid 29522193)
87. Belal M, Abrams P. Noninvasive methods of diagnosing bladder outlet obstruction in men. Part 1: nonurodynamic approach. J Urol 2006;176:22-8. (Pubitemid 43815398)
88. Lourenco T, Pickard R, Vale L, Grant A, Fraser C, MacLennan G, et al. Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials. BMJ 2008;337:a1662.
89. Hawary A, Mukhtar K, Sinclair A, Pearce I. Transurethral resection of the prostate syndrome: almost gone but not forgotten. J Endourol 2009;23:2013-20.
90. Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Mermanek P, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol 2008;180:246-9.
91. Omar MI, Lam TB, Alexander CE, Graham J, Mamoulakis C, Imamura M, et al. Systematic review and meta-analysis of the clinical effectiveness of bipolar compared with monopolar transurethral resection of the prostate (TURP). BJU Int 2014;113:24-35.
92. Schulman CC, Zlotta AR, Rasor JS, Hourriez L, Noel JC, Edwards SD. Transurethral needle ablation (TUNA): safety, feasibility, and tolerance of a new office procedure for treatment of benign prostatic hyperplasia. Eur Urol 1993;24:415-23. (Pubitemid 23306230)
93. Bouza C, Lopez T, Magro A, Navalpotro L, Amate JM. Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol 2006;6:14.
94. Jepsen JV, Bruskewitz RC. Recent developments in the surgical management of benign prostatic hyperplasia. Urology 1998;51(4A suppl):23-31.
95. Hoffman RM, Monga M, Elliott SP, Macdonald R, Langsjoen J, Tacklind J, et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev 2012;9:CD004135.
96. Fabian KM. [The intra-prostatic "partial catheter" (urological spiral) (author's transl)]. Urologe A 1980;19:236-8.
97. Guazzoni G, Montorsi F, Coulange C, Milroy E, Pansadoro V, Rubben H, et al. A modified prostatic UroLume Wallstent for healthy patients with symptomatic benign prostatic hyperplasia: a European Multicenter Study. Urology 1994;44:364-70. (Pubitemid 24273819)
98. Woo HH, Chin PT, McNicholas TA, Gill HS, Plante MK, Bruskewitz RC, et al. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 2011;108:82-8.
99. National Insitute for Health and Care Excellence. Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. 2014. www.nice.org.uk/Guidance/IPG475.
100. Anson K, Nawrocki J, Buckley J, Fowler C, Kirby R, Lawrence W, et al. A multicenter, randomized, prospective study of endoscopic laser ablation versus transurethral resection of the prostate. Urology 1995;46:305-10.
101. Cowles RS, 3rd, Kabalin JN, Childs S, Lepor H, Dixon C, Stein B, et al. A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. Urology 1995;46:155-60.
102. Gilling PJ, Cass CB, Cresswell MD, Malcolm AR, Fraundorfer MR. The use of the holmium laser in the treatment of benign prostatic hyperplasia. J Endourol 1996;10:459-61. (Pubitemid 26385825)
103. Mackey MJ, Chilton CP, Gilling PJ, Fraundorfer M, Cresswell MD. The results of holmium laser resection of the prostate. Br J Urol 1998;81:518-9. (Pubitemid 28316577)
104. Malek RS, Kuntzman RS, Barrett DM. High power potassium-titanyl-phosphate laser vaporization prostatectomy. J Urol 2000;163:1730-3. (Pubitemid 30366723)
105. Fried NM, Murray KE. High-power thulium fiber laser ablation of urinary tissues at 1.94 microm. J Endourol 2005;19:25-31. (Pubitemid 40365739)
106. Biester K, Skipka G, Jahn R, Buchberger B, Rohde V, Lange S. Systematic review of surgical treatments for benign prostatic hyperplasia and presentation of an approach to investigate therapeutic equivalence (non-inferiority). BJU Int 2012;109:722-30.
107. Teng J, Zhang D, Li Y, Yin L, Wang K, Cui X, et al. Photoselective vaporization with the green light laser vs transurethral resection of the prostate for treating benign prostate hyperplasia: a systematic review and meta-analysis. BJU Int 2013;111:312-23.
108. Xia SJ, Zhuo J, Sun XW, Han BM, Shao Y, Zhang YN. Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. Eur Urol 2008;53:382-9.
109. Yu X, Elliott SP, Wilt TJ, McBean AM. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. J Urol 2008;180:241-5; discussion 245.
110. Karsenty G, Denys P, Amarenco G, De Deze M, Game X, Haab F, et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 2008;53:275-87. (Pubitemid 350296587)
111. Patel AK, Patterson JM, Chapple CR. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Eur Urol 2006;50:684-709; discussion 709-10.
112. Chuang YC, Tu CH, Huang CC, Lin HJ, Chiang PH, Yoshimura N, et al. Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urol 2006;6:12.
113. Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA. Botox-induced prostatic involution. Prostate 1998;37:44-50. (Pubitemid 28385184)
114. Oeconomou A, Madersbacher H, Kiss G, Berger TJ, Melekos M, Rehder P. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. Eur Urol 2008;54:765-75.
115. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003;62:259-64; discussion 264-5.
116. Marberger M, Chartier-Kastler E, Egerdie B, Lee KS, Grosse J, Bugarin D, et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with with benign prostatic hyperplasia. Eur Urol 2013;63:496-503.
117. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18. (Pubitemid 40385459)
118. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011;208:1339-50.
119. Ma J, Gharaee-Kermani M, Kunju L, Hollingsworth JM, Adler J, Arruda EM, et al. Prostatic fibrosis is associated with lower urinary tract symptoms. J Urol 2012;188:1375-81.
120. Gharaee-Kermani M, Macoska JA. Promising molecular targets and biomarkers for male BPH and LUTS. Curr Urol Rep 2013;14:628-37.